Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study | Zendy

Vincenzo Panichi | Zendy; Alberto Rosati | Zendy; Roberto Bigazzi | Zendy; Sabrina Paoletti | Zendy; Elide Mantuano | Zendy; S. Beati | Zendy; Veronica Marchetti | Zendy; G. Bernabini | Zendy; Giovanni Grazi | Zendy; Giovanni Manca Rizza | Zendy; M. Migliori | Zendy; Robert Giusti | Zendy; A. Lippi | Zendy; A. Casani | Zendy; Giovanni Barsotti | Zendy; Ciro Tetta | Zendy

Open Access

Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study

Author(s) -

Vincenzo Panichi,

Alberto Rosati,

Roberto Bigazzi,

Sabrina Paoletti,

Elide Mantuano,

S. Beati,

Veronica Marchetti,

G. Bernabini,

Giovanni Grazi,

Giovanni Manca Rizza,

M. Migliori,

Robert Giusti,

A. Lippi,

A. Casani,

Giovanni Barsotti,

Ciro Tetta

Publication year - 2011

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfq802

Subject(s) - medicine , erythropoiesis , inflammation , erythropoietin , disease , hemodialysis , anemia , intensive care medicine , kidney disease , immunology

Resistance to erythropoiesis-stimulating agents (ESAs) is often associated with chronic inflammation. Here, we investigated how anaemia, ESA resistance and the plasma levels of biological markers of inflammation could influence all-cause and cardiovascular disease morbidity and mortality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research